Rua Bioscience reports revenue growth, seeks further capital

Rua Bioscience announced a significant increase in revenue for FY25, reaching $1.90m, up from $0.32m in FY24. Revenue from customers also saw a substantial rise to $1.51m from $86K in the previous year. The company reported a reduced loss before tax of $3.46m for FY25, compared to $13.72m in FY24, indicating strong momentum expected to continue into FY26.

Despite this growth, the company noted it would require additional capital to meet minimum expenditure commitments and support ongoing operations, as forecasts indicate insufficient cash for the next 12 months. Since June 30, 2025, Rua secured a further $1.26m through equity and debt, primarily for inventory. Operational highlights include record monthly sales in Australia and New Zealand, market entry in Czechia, and product launches in Germany and growth in the United Kingdom.

Rua’s strategy remains focused on genetics and distribution, translating into tangible commercial results across five key markets. The board is actively working with shareholders and advisors to explore further capital raise options to support growing sales demand and accelerate growth.